MHC Class I Molecules and Progression to AIDS by Carrington, Mary et al.
Nova Southeastern University
NSUWorks
Biology Faculty Articles Department of Biological Sciences
9-20-2001
MHC Class I Molecules and Progression to AIDS
Mary Carrington
National Cancer Institute at Frederick
Xiaojiang Gao
National Cancer Institute at Frederick
Stephen J. O'Brien
National Cancer Institute at Frederick, sobrien1@nova.edu
Follow this and additional works at: http://nsuworks.nova.edu/cnso_bio_facarticles
Part of the Genetics and Genomics Commons, and the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Department of Biological Sciences at NSUWorks. It has been accepted for inclusion in
Biology Faculty Articles by an authorized administrator of NSUWorks. For more information, please contact nsuworks@nova.edu.
NSUWorks Citation
Carrington, Mary; Xiaojiang Gao; and Stephen J. O'Brien. 2001. "MHC Class I Molecules and Progression to AIDS." New England
Journal of Medicine 345, (12): 924-925. http://nsuworks.nova.edu/cnso_bio_facarticles/792
 924
 
·
 
N Engl J Med, Vol. 345, No. 12
 
·
 
September 20, 2001
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
limited to patients with tumors 5 cm or less in diameter,
long-term survival approaches 75 percent at four years,
whereas transplantation in those with tumors larger than
5 cm has been associated with less than 30 percent surviv-
al.
 
2,3
 
 These data led to the exclusion of patients with larger
tumors from the waiting list for cadaveric organs. We sug-
gest that if the supply of cadaveric organs were to exceed the
current demand, patients with the worst outcomes would be
considered candidates. Can we now refuse to offer these pa-
tients transplantation when a healthy living donor provides
the graft?
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The authors reply:
 
To the Editor:
 
 We agree with most of the views of Miller
and Delmonico, including their conclusions that the “trans-
plantation community . . . does indeed monitor itself ” and
that it shows “concern for the well-being of living donors.”
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In our article, we never question this commitment. We
also agree that the surgical model of innovation based on
professional self-regulation rather than administrative reg-
ulation has proved to be an extremely effective way to ad-
vance the field of surgery to benefit patients.
Our disagreement with Miller and Delmonico focuses
on whether the professional regulatory model involving con-
ferences, colloquiums, and position papers will prove ade-
quate for dealing with the transplantation of liver grafts
from adult living donors and for protecting potential do-
nors. We believe that the best way to optimize the use of
this innovative technology is to define clearly the experimen-
tal protocol, standardize the operation, ensure the “field
strength” of the surgical team, and record and share all
data on outcomes (including program-specific data) with
the professional community and with patients. If the pro-
fessional community can accomplish these tasks quickly —
and thus far they have not — there may not be a need for
formal regulatory control.
Shaked and Lucey highlight an unresolved issue with re-
gard to recipients. Since the four-year survival among pa-
tients who have hepatocellular carcinomas larger than 5 cm
and undergo transplantation is so poor,
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 this group has been
excluded from the waiting list for cadaveric organs. Shaked
and Lucey suggest that living donors be subjected to com-
plications and possibly death to provide grafts to recipients
with hepatocellular carcinomas, even though the transplan-
tation community has declined to use cadaveric grafts in such
patients. In our article, we refer to the need to balance the
short-term and long-term risks to the donor with the poten-
tial benefits to the recipient. The proposal offered by Shaked
and Lucey demonstrates the need for the transplantation
community to specify what outcomes in a recipient are ac-
ceptable before a living donor is subjected to surgical risk.
It also raises the question of whether individual programs
can be required to comply with standards established by the
surgical transplantation community through professional
self-regulation.
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MHC Class I Molecules and Progression 
to AIDS
 
To the Editor:
 
 Gao et al. (May 31 issue)
 
1
 
 report the iden-
tification of specific HLA-B*35-Px subtypes as responsible
for the association between HLA-B*35 and rapid progres-
sion to AIDS, and they stress the importance of homozygos-
ity for HLA-B*35 as a predictor of even more rapid progres-
sion. Their extensive analysis confirms the known protective
effect of the HLA-B*27 and B*57 subtypes against pro-
gression to AIDS, at least in whites.
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Unlike Gao and colleagues, we think that there is an im-
portant influence of numerous major-histocompatibility-
complex (MHC) gene products. The A1,B8,DR3 haplotype,
for instance, has repeatedly been shown to be associated
with fast progression to human immunodeficiency virus
(HIV) disease and rapid loss of CD4 T cells,
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 and several
other HLA haplotypes can predict disease progression.2
Caution should be exercised before early, aggressive antiret-
roviral therapy is recommended for HLA-B*35–positive
patients. We have been following an HIV-infected woman
without symptoms since her seroconversion in 1991 (she is
now 37 years old). She has never received antiretroviral ther-
apy and still has a high CD4 cell count (606 per cubic mil-
limeter, 36.6 percent of total lymphocytes) and CD4:CD8
ratio (0.91), despite being homozygous for HLA-B*35. Per-
haps the presence of HLA A2,A26 alleles in her haplotype
counteracts the effects of HLA-B*35, since A2 is common
in frequently exposed HIV-seronegative persons5 and A26
may confer resistance to the progression of HIV disease.2
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The authors reply:
To the Editor: To date, over 50 papers have been pub-
lished that attempt to associate HLA haplotypes with the
rate of progression to AIDS. Because of low statistical pow-
er and small samples, the results of many cannot be con-
sidered rigorously validated. Among the strongest associ-
ations are the influence of HLA class I homozygosity and
the codominant influence of HLA-B*35. The goal of our
recent report was to demonstrate that the previously report-
ed effect of B*351 could be connected directly to the pep-
tide-binding specificity of certain HLA-B*35 subtypes. We
are, of course, aware of several other genetic factors that
mitigate progression to AIDS, including the genes encod-
ing CC chemokine receptors 5 and 2, interleukin-10, and
stromal-cell–derived factor 1 as well as other HLA alleles,
and we described them in our cohorts.1,2 These factors may
counteract each other, which could be the case for the
HLA-B*35–homozygous woman described by Cainelli et al.
This patient’s AIDS-free survival for 10 years is remark-
able. In our experience with six patients homozygous for
HLA-B*35 in five cohorts, five progressed to an AIDS-
defining condition in less than 6 years and the other one
in less than 10 years.
We agree that multiple genetic and viral influences should
be considered when a therapeutic regimen for an HIV-
infected patient is chosen. We believe that B*35-Px is one
of the more influential factors.
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Spironolactone in Addition to ACE Inhibition 
to Reduce Proteinuria in Patients with Chronic 
Renal Disease
To the Editor: Angiotensin-converting–enzyme (ACE)
inhibitors have been shown to reduce proteinuria and slow
the progression of renal disease.1 Although to date angio-
tensin II has been the focus of attention as the primary me-
diator of the renin–angiotensin–aldosterone system, several
studies have raised the possibility that aldosterone itself has
a role in mediating progressive renal disease.2,3 Pitt et al.4
showed that blockade of aldosterone receptors by spirono-
lactone significantly reduced the risk of morbidity and death
among patients with heart failure who were already receiving
ACE inhibitors. The authors hypothesized that the benefits
were not due to the hemodynamic effects of spironolac-
tone but, instead, may have been due to an adverse effect
of aldosterone on myocardial and vascular smooth-muscle
cells. We tested the hypothesis that spironolactone may act
along with ACE inhibitors in the kidney to reduce pro-
teinuria.
*P<0.02 for the comparison between pretreatment and post-treatment urinary protein, by the paired t-test. There were no other significant differences
between pretreatment and post-treatment values.
TABLE 1. CLINICAL CHARACTERISTICS AND FINDINGS BEFORE AND AFTER TREATMENT WITH SPIRONOLACTONE IN EIGHT PATIENTS.
SEX AGE URINARY PROTEIN CREATININE CLEARANCE SYSTOLIC PRESSURE DIASTOLIC PRESSURE DIAGNOSIS
BEFORE 
TREATMENT
AFTER 
TREATMENT
BEFORE 
TREATMENT
AFTER 
TREATMENT
BEFORE 
TREATMENT
AFTER 
TREATMENT
BEFORE 
TREATMENT
AFTER 
TREATMENT
yr g/day ml/sec mm/Hg
Male 62 2.87 0.94 1.30 0.66 120 120 80 70 Type 2 diabetes
Male 60 8.90 3.30 0.58 0.59 120 110 80 70 Type 2 diabetes
Female 43 2.83 2.94 2.50 2.02 120 110 90 70 Systemic lupus erythematosus
Male 71 3.00 1.80 0.62 0.45 200 170 100 90 Type 2 diabetes
Male 55 2.21 0.86 2.40 3.90 170 130 90 80 Type 2 diabetes
Male 74 6.17 2.02 1.24 1.30 120 130 90 80 Focal sclerosis with segmen-
tal hyalinosis
Male 61 1.17 0.36 1.71 1.51 140 160 90 70 Type 2 diabetes
Female 31 3.30 1.75 0.48 0.53 120 115 90 80 Vasculitis
Mean ±SD* 3.81±2.50 1.75±1.02 1.35±0.80 1.37±1.17 138.8±30.4 130.6±22.7 88.8±6.4 76.3±7.4
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